ADX48621
ADX48621 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM), which may have potential in multiple indications. The lead indication for the product is levodopa associated dyskinesia in Parkinson's disease. ADX48621 also is a backup for ADX10059 in GERD and migraine.
ADX48621 has completed an initial Phase I trial. In this first-in-man single ascending dose study, the orally administered product was well tolerated.
The ADX48621 Phase I program is scheduled to be completed in 2008. Phase IIa proof of concept studies in levodopa associated dyskinesia in Parkinson's patients are schedule to start in the first half of 2009.
Back to pipeline